Breaking News

Rentschler Biotechnologie Names CEO

January 8, 2016

Mathias has more than 25 years of pharma and biopharma experience

Dr. Frank Mathias has been appointed chief executive officer of Rentschler Biotechnologie, effective 1 April 2016. Dr. Mathias was previously a member of the company’s supervisory board.
 
Former chief executive, Dr. Nikolaus F. Rentschler, is moving to the supervisory board to oversee further expansion of the Rentschler group.
 
Dr. Mathias has more than 25 years of experience in the pharma and biopharma industries. He served as chief executive officer of Servier Deutschland and Amgen Deutschland and in 2009 became chief executive officer at Medigene AG.
 
Dr. Rentschler said, “We are glad to have been able to take on such an experienced and successful CEO for Rentschler Biotechnologie. He is an expert in this business and has been familiar with the company’s topics for years. The shareholder, Members of the Supervisory Board and Management Board are looking forward to the cooperation.”
 
Dr. Frank Mathias, “I am impressed by the dynamics and the strong commitment of the leaders and staff of this growing company. On this basis and owing to continuously positive developments on the market we will jointly lead Rentschler Biotechnologie to future success.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision